SCHEMBL25256819

SCHEMBL25256819

COCc1ccccc1NC(=O)/C=C/c1ccc2cnn(C3CCCCO3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACKR3 P25106 1/20 0.42
▸ KDM1A O60341 2/20 0.41
▸ RXRA P19793 1/20 0.40
▸ RXRB P28702 1/20 0.40
▸ RXRG P48443 1/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CCR3 P51677 1/20 0.38
▸ S1PR1 P21453 2/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ HIF1A Q16665 2/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29410364 0.91 ACKR3 (0.41) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL29410333 0.91 KDM1A (0.45) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL29410330 0.91 ACKR3 (0.41) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL25246315 0.91 ACKR3 (0.41) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL25250405 0.91 KDM1A (0.45) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL29410356 0.91 KDM1A (0.45) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL25249882 0.91 ACKR3 (0.41) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL25249510 0.91 KDM1A (0.45) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL25298988 0.91 ACKR3 (0.42) ACKR3KDM1ARXRARXRBRXRG
SCHEMBL25252295 0.91 ACKR3 (0.42) ACKR3KDM1ARXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497359-B2 Acrylamide derivatives NRG THERAPEUTICS LTD (GB) 2025-12-16 — — US disclosed
EP-4208448-B1 ACRYLAMIDE DERIVATIVES NRG THERAPEUTICS LTD (GB) 2025-04-23 — — EP disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
US-20230312466-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-10-05 — — US disclosed
EP-4208448-A1 NOVEL COMPOUNDS NRG Therapeutics LTD (GB) 2023-07-12 — — EP disclosed
WO-2022049377-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2022-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312466-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 ACKR3 291/4885KDM1A 3853/4885RXRA 1559/4885
US-12497359-B2 Acrylamide derivatives ACR, GSTA2, GSTA1 ACKR3 3198/4885KDM1A 3893/4885RXRA 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback